Prophylactic administration of sclerostin antibody to CIA mice prevents systemic bone loss. (A, D) Representative three-dimensional renditions of the trabecular bone within the L5 vertebral body and the tibial metaphysis, respectively, scanned by micro computed tomography. (B, C) Bar plots represent mean (and standard deviation) of the trabecular bone volume fraction (BV/TV) in the vertebral body and the trabecular thickness (Tb.Th). (E, F) Bar plots represent mean (and standard deviation) of the trabecular bone volume fraction (BV/TV), the tibial metaphysis and the cortical thickness of the cortical bone in the tibia midshaft. (G) Bar plot represents mean (and standard deviation) of the bone mineral density (BMD) assessed by dual-energy X-ray absorptiometry (DEXA). The groups treated with PBS or sclerostin antibody (Scl-AbI) were split into diseased (PBS n = 11, Scl-AbI n = 11) and non-diseased mice (PBS n = 4, Scl-AbI n = 4). A group of age-matched healthy controls (CTR n = 6) were used to determine baseline bone mineral density (BMD). The one-way ANOVA test with Tukey's post hoc comparison was used for statistical evaluation of all parameters shown in the bar plots. *P < 0.05 for the difference versus CTR; #P < 0.05 for the difference versus collagen-induced arthritis (CIA) + PBS (and diseased/non-diseased PBS in graph G).
Marenzana et al. Arthritis Research & Therapy 2013 15:R125 doi:10.1186/ar4305